XOLACTAThe power and potential of XoLacta
XoLacta contains revolutionary, proprietary drugs, using milk-derived exosomes as a novel drug delivery platform — able to signal, target and offload vital therapies to the exact site where they’re needed most.
HOW IT WORKSXoLacta
1. Loading
Our uniquely isolated milk-derived exosomes are loaded with our ⍺ct-11 peptide to create a powerful new drug, XoLacta.
2. Homing
When orally administered prophylactically, or even 24 hours following injury, XoLacta is taken up by the cells of injured tissue where it's needed most.
3. Offloading
The ⍺ct-11 peptides are released into cells, arresting the bystander effect to prevent the cascade of cell death and scar formation.
APPLICATIONSLife-changing benefits for patients
We’re currently investigating the use of XoLacta as an orally-administered whole-body protection for both prophylactic and post-exposure use against lethal, therapeutic and background radiation.
PROACTIVE RADIATION PROTECTANTProtection from high levels of background radiation
“Milk exosomes contain the potential to stand as a new modality of drug delivery — with an all-natural packaging system, Tiny Cargo is poised to revolutionize peptide therapeutics”
Spencer Marsh
Chief Scientific Officer
The Tiny Cargo Company
MEDICAL COUNTERMEASURETreating exposure to high doses of ionizing radiation
We live in a nuclear world, yet currently there are zero treatments for exposures to high doses of ionizing radiation — we aim to change that.
As a member of the BLUE KNIGHT™ incubator, XoLacta has been reviewed as a Radiotherapeutic Medical Countermeasure by mentors at the Biomedical Advanced Research and Development Authority (BARDA).
FULL BODY RADIOPROTECTANTProtecting healthy cells during radiation exposure
The side effects of radiation exposure during cancer treatment can be devastating, yet there is currently no systemically effective treatment for tissue injury sustained during radiotherapy.
XoLacta is being developed as the first whole-body radioprotectant therapy with potentially life-changing impacts for cancer patients around the world.
Fast and Effective
Pre-clinical in vivo studies show an increase in survival rates of 40% - 70% from 1 dose (0.5 mg/kg) of orally-administered XoLacta, when given before or up to 24 hours following lethal (14 Gy) radiation exposure.
24hrs
Window
↑ 40%+
Survival rates
Regulatory Approval Timeline
We’re underway with the process to secure regulatory approval from the U.S. Food and Drug Administration (FDA) for the use of XoLacta for both adjuvant therapy and as a medical countermeasure via the ‘Animal Rule’ regulatory pathway.
RESOURCES